RxDoctor Payments Data

Mia Kim, NP

Nurse Practitioner · Orange, CANPI 1689917494

Payments from drug & device makers

$727in general payments, 2019–2025

Across 25 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$205
  • Boston Scientific$139
  • Neurocrine Biosciences, Inc.$120
  • Merz Pharmaceuticals, LLC$88
  • Upsher-smith Laboratories LLC$49
  • Eisai Inc.$28
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$727 in reported general payments places this provider in the 75th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$86,496
Medicare patients
538
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl417$31,747
Nurtec OdtRimegepant Sulfate16$27,829
Emgality PenGalcanezumab-Gnlm41$27,532
UbrelvyUbrogepant20$17,783
Memantine Hcl ErMemantine Hcl92$11,905
QuliptaAtogepant11$9,126
Aimovig AutoinjectorErenumab-Aooe11$7,322
Levetiracetam45$5,417
Rivastigmine22$4,906
Donepezil Hcl237$3,454
Galantamine ErGalantamine Hbr38$2,898
Galantamine Hbr19$1,846
Sertraline Hcl135$1,717
RivastigmineRivastigmine Tartrate12$1,432
Quetiapine Fumarate87$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$205$26,90931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →